Related Experiment Video
Updated: May 27, 2025
09:44
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
2.9K
Metformin dosage and galectin-3 levels: insights from PCOS patients preparing for IVF
Valentina N Nikolić1, Milan Stefanović2,3, Dejan Mitić2,3
1Department of Pharmacology with Toxicology, University of Nis Faculty of Medicine, Niš, Serbia.
Frontiers in Pharmacology
|February 17, 2025
Summary
Metformin dosage and hyperprolactinemia impact galectin-3 levels in women with Polycystic Ovary Syndrome (PCOS). Dosage, not drug levels, appears key for galectin-3 regulation in PCOS management.
Area of Science:
- Endocrinology and Reproductive Medicine
- Metabolic Disorders
- Biomarker Discovery
Background:
- Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder with significant metabolic and hormonal implications.
- Galectin-3 is emerging as a potential biomarker in PCOS, but its regulation by key therapeutic agents and hormonal factors is not fully understood.
- Metformin is a cornerstone therapy for PCOS, yet its precise impact on biomarkers like galectin-3 requires further elucidation.
Purpose of the Study:
- To investigate the relationship between metformin dosage, hyperprolactinemia, and galectin-3 levels in women with PCOS.
- To explore the influence of these factors on metabolic and hormonal regulation within the context of PCOS.
- To provide novel insights into the management of PCOS and identify potential therapeutic targets.
Main Methods:
- Analysis of a cohort of 53 women diagnosed with PCOS using the Rotterdam criteria.
- Measurement of metformin concentrations using high-performance liquid chromatography (HPLC).
- Quantification of galectin-3 levels via enzyme-linked immunosorbent assay (ELISA).
Main Results:
- Significant statistical associations were found between metformin dosage and galectin-3 levels.
- Hyperprolactinemia was also significantly associated with galectin-3 levels in women with PCOS.
- Body mass index (BMI) did not show a significant association with galectin-3 levels.
- Correlation between galectin-3 and metformin concentration was weak or absent after adjusting for daily dose, suggesting dose and duration are critical.
Conclusions:
- Galectin-3 levels in PCOS appear to be influenced more by metformin dosage and duration than absolute drug concentrations.
- Hyperprolactinemia is a significant factor associated with galectin-3 levels in this PCOS cohort.
- Findings suggest galectin-3 regulation may involve pathways independent of metformin pharmacokinetics, offering new avenues for personalized PCOS management.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
158
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
158
01:22Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164